Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Killian who wrote (53357)	3/18/2000 6:02:00 PM
From: sam	Respond to of 122087

Interesting take on the CEGE situation. Genetic Capital seems to think that the market is not valuing CEGE's technology at a significant discount...but rather valuing CEGE's ABGX holdings at a discount. They value CEGE net ABGX at $650m. Thus, CEGE's ABGX holdings are trading at $113 a share (or $160 less than ABGX shares trade on the open market). Savvy investors or arbs should notice they can get ABGX VERY cheaply simply by buying CEGE (rather than ABGX). But, since this is obviously not working out according to plan, Genetic Capital suggests CEGE should spin off its ABGX holdings so that it can gain its true value from the market.